Akcea Therapeutics

Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., the leader in RNA therapeutics. Akcea commercializes TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis’ proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil, and WAYLIVRA is approved in the E.U.

Pam Mersinger
Rare Disease Specialist – Chicago South
Akcea Therapeutics
Cell: 312.882.9716

Follow on social Media
Patient Video of Larry & Rod
Meet Larry and Rod – brothers diagnosed with hereditary ATTR amyloidosis. Before receiving his diagnosis at the age of 72, Larry saw many doctors, while noticing his symptoms becoming progressively debilitating. Larry’s diagnosis opened the door to the genetic testing of his siblings, which is how Rod learned that he too has the rare disease.
hATTR Amyloidosis Symptom Checklist for Patients
hATTR Diagnostic Card – Cardiologists
hATTR Amyloidosis Brochure Overview